SC 13G/A: BridgeBio Pharma, Inc.

AI Summary

SC 13G/A filing by BridgeBio Pharma, Inc..

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.001 — ame of issuer) Common Stock, par value $0.001 per share (Title of class of securitie

Filing Documents

• ef20021932_sc13ga.htm (SC 13G/A) — 55KB
• 0001140361-24-008424.txt ( ) — 56KB

From the Filing

SC 13G/A 1 ef20021932_sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)* BridgeBio Pharma, Inc. (Name of issuer) Common Stock, par value $0.001 per share (Title of class of securities) 10806X 102 (CUSIP number) 12/31/2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) (Continued on the following pages) SCHEDULE 13G CUSIP No. 10806X 102 1 NAMES OF REPORTING PERSONS NEIL KUMAR 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION U.S. NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 4,813,197 6 SHARED VOTING POWER 2,008,408 7 SOLE DISPOSITIVE POWER 4,813,197 8 SHARED DISPOSITIVE POWER 2,008,408 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,959,504 (1) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.59% (2) 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN (1) Consists of (i) 4,813,197 shares of Common Stock held directly by Dr. Kumar, (ii) 3,035,650 shares of Common Stock issuable to Dr. Kumar upon the exercise of stock options exercisable within 60 days of December 31, 2023, (iii) 102,249 shares of Common Stock issuable to Dr. Kumar upon the vesting and settlement of restricted stock units within 60 days of December 31, 2023, (iv) 1,012,722 shares of Common Stock held by the Kumar Haldea Revocable Trust, of which Dr. Kumar is a co-trustee and (v) 995,686 shares of Common Stock held by the Kumar Haldea Family Irrevocable Trust, of which Dr. Kumar is a co-trustee. (2) Percentage ownership is based on (i) 175,082,951 shares of Common Stock outstanding as of December 31, 2023, (ii) 3,035,650 shares of Common Stock underlying stock options held by Dr. Kumar that are exercisable within 60 days of December 31, 2023 and are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i) and (iii) 102,249 shares of Common Stock underlying restricted stock units held by Dr. Kumar that are subject to vesting and settlement within 60 days of December 31, 2023 and are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i). Page 2 of 6 Item 1 (a) Name of Issuer: BridgeBio Pharma, Inc. (b) Address of Issuer's Principal Executive Offices: 3160 Porter Street, Suite 250, Palo Alto, CA 94301 Item 2 (a) Name of Person Filing: Neil Kumar (b) Address of Principal Business Office or, if None, Residence: 3160 Porter Street, Suite 250, Palo Alto, CA 94301 (c) Citizenship: U.S. (d) Title of Class of Securities: Common Stock, par value $0.001 per share (e) CUSIP Number: 10806X 102 Item 3 If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); Page 3 of 6 (g) A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: . Item 4 Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: 9,959,504 shares of Common Stock, which represents (i) 4,813,197 shares held of record by Neil Kumar, (ii) 3,035,650 shares of Common Stock issuable to Dr. Kumar upon the exercise of stock options exercisable within 60 days of December 31, 2023, (iii) 102,249 shares of Common Stock issuable to Dr. Kumar upon the vesting and settlement of restricted stock units within 60 days of December 31, 2023, (iv) 995,686 shares held of record by the Kumar Haldea Family Irrevocable Trust and (v)

View Full Filing

View this SC 13G/A filing on SEC EDGAR